Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
AssigneeVaccinex, Inc.
InventorsErnest S. SMITH, Maurice Zauderer
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
Claims21
A method of decreasing blood brain barrier permeability in a subject having a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D), thereby decreasing blood brain barrier permeability in the subject.
(canceled)
(canceled)
The method of any one of claim 1, 2, 4, 6, 7 or 21, wherein the binding molecule competitively inhibits a reference monoclonal antibody selected from the group consisting of VX15/2503 or 67 from specifically binding to SEMA4D.
A method of decreasing blood-brain barrier permeability in a subject having a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to SEMA4D, wherein the binding molecule competitively inhibits a reference monoclonal antibody selected from the group consisting of VX15/2503 or 67 from specifically binding to SEMA4D, thereby decreasing blood brain barrier permeability in the subject.
(canceled)
A method of treating a subject having a neuroinflammatory disorder, comprising administering to the subject an effective amount of an inhibitor of semaphorin 4D (SEMA4D) interaction with a SEMA4D receptor, wherein the inhibitor decreases permeability of the blood-brain barrier, thereby treating the subject.
Dependencies are inferred from the claim text.